Nuclear Signaling Pathways and Targeting Transcription in Cancer - Cancer Drug Discovery and Development 2013 edition

Marc Notes: Includes bibliographical references and index. Table of Contents: Preface.- Steroid Receptor Coactivators (SRCs) as Integrators of Multiple Signaling Pathways in Cancer Progression.- Role of Alteration/Deficiency in Activation (ADA) Complex in the Cell Cycle, Genomic Instability and Cancer.- RUNX2 Transcriptional Regulation in Development and Disease.- Epigenetic Mechanisms of Cancer Metastasis.- Regulatory Effects of Arsenic on Cellular Signaling Pathways: Biological Effects and Therapeutic Implications.- Nuclear Factors Linking Cancer and Inflammation.- Regulation of the Jak/STATs Pathways by Histone Deacetylases.- Receptor Tyrosine Kinases in the Nucleus: Nuclear Functions and Therapeutic Implications in Cancers.- Nucleolar Signaling Determines Cell Fate The RP-Mdm2-p53 Axis Fine-Tunes Cellular Homeostasis.- Transcriptional Regulation of Lipogenesis as a Therapeutic Target for Cancer Treatment.- Selective Inhibition of Acetyl-Lysine Effector Domains of the Bromodomain Family in Oncology.- Domain Specific Targeting of Cancer.- The Potential of Targeting Splicing for Cancer Therapy.- Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies.- Histone Demethylases in Prostate Cancer.- Therapeutic Significance of Chromatin Remodeling Complexes in Cancer.- Index."Jacket Description/Back: This book presents the most up-to-date information in the area of targeted therapeutics with a particular focus on pathway-centered approaches and transcription by leading authorities in molecular cancer research. The goal is to cover several critical principles of cancer therapeutics, ranging from regulation of cancer associated genes by coregulators, cancer cell signaling, modifiers of epigenome functionality and specific protein domains, and emerging significance of splicing. The book is directed for basic and translational scientists, clinicians, clinical investigators, fellows, residents, graduate students, and educators in the areas of molecular therapeutics and cancer medicine, and medical sciences at-large. Readers will be able to grasp the overall importance of the pathway, associated pathobiology and clinical manifestation, and possible points of intervention with a goal to solidify new cancer therapeutic targets. Publisher Marketing: Nuclear Signaling Pathways and Targeting Transcription in Cancer

Contributor Bio:  Kumar, Rakesh Rakesh Kumar is a semiconductor industry veteran with extensive experience in managing IC implementation in both fabless and fab environments. He is the Founding Partner and President of TCX, Inc., a company that has assisted many fabless companies. He has held technical and executive positions at Cadence Design Services, Unisys, and Motorola. Dr. Kumar serves on the executive committees of the IEEE Solid-State Circuits Society and the IEEE Engineering Management Council.